M1003 HCPCS Level II code: Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy
M1003 is the HCPCS code for “Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
M1003Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy
Short description: Tb scr 12 mo pri fst bio dz
HCPCS · United States
Medicare details
The indicators CMS publishes with M1003 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Medical care
- BETOS category
- Undefined codes
- Added
- Jan 1, 2019
Where M1003 sits
- 1M codesMedical services and quality measures
- 2Active code M1003Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code M1003 mean?
M1003 is the HCPCS code for “Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover M1003?
CMS lists M1003’s Medicare coverage as “Carrier judgment” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside M1003
All M codesM0250Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require…M0300Iv chelation therapy (chemical endarterectomy)M0301Fabric wrapping of abdominal aneurysmM1000Pain screened as moderate to severeM1001Plan of care to address moderate to severe pain documented on or before the date of the second visit with a clinicianM1002Plan of care for moderate to severe pain not documented on or before the date of the second visit with a clinician, reason not givenM1004Documentation of medical reason for not screening for tb or interpreting results (i.e., patient positive for tb and documentation of past treatment; patient who has recently…M1005Tb screening not performed or results not interpreted, reason not givenM1006Disease activity not assessed, reason not givenM1007>=50% of total number of a patient's outpatient ra encounters assessedM1008<50% of total number of a patient's outpatient ra encounters assessedM1009Discharge/discontinuation of the episode of care documented in the medical record